Literature DB >> 26921083

A Randomized Controlled Comparison of Esophageal Clearance Times of Oral Budesonide Preparations.

Jody N Hefner1,2, Robin S Howard3, Robert Massey4, Miland Valencia4, Derek J Stocker4, Katherine Q Philla5,6, Matthew D Goldman5,6, Cade M Nylund5,6, Steve B Min5,6.   

Abstract

BACKGROUND: Topical steroids prepared as oral viscous slurries have become common in the treatment of eosinophilic esophagitis. Esophageal mucosal contact time correlates with clinical and histologic improvement. AIM: To compare the mucosal contact time of alternative oral viscous budesonide (OVB) slurries with the conventional sucralose OVB.
METHODS: A blinded randomized crossover trial investigating esophageal clearance of three OVB slurry preparations was done on healthy adults. Honey and xanthan gum OVB slurries were compared with standard sucralose OVB in 24 randomly assigned subjects. Each subject ingested the sucralose OVB and either the honey or xanthan gum OVB slurries. The esophageal clearance of each slurry was evaluated as an area under the curve (AUC) using 1 millicurie of technetium-99m-sulfur colloid (Tc99) co-administered in each OVB preparation using nuclear scintigraphy. A standardized taste survey was also administered.
RESULTS: Xanthan gum had greater mucosal contact time compared to sucralose as measured by a higher AUC at 3 min (P = 0.002), while honey showed no significant difference in esophageal clearance relative to sucralose. Taste scores were significantly higher in the honey group, while scores for xanthan gum were no different from standard sucralose.
CONCLUSION: OVB slurries utilizing xanthan gum may be a superior alternative to a sucralose-based slurry due to its increased mucosal contact time and similar taste tolerance. Honey may be a suitable alternative as well, due to its similar contact time and favorable taste.

Entities:  

Keywords:  Budesonide; Eosinophilic esophagitis; Honey; OVB; Viscous budesonide slurry; Xanthan gum

Mesh:

Substances:

Year:  2016        PMID: 26921083     DOI: 10.1007/s10620-015-3990-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

1.  Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.

Authors:  Ranjan Dohil; Robert Newbury; Lyman Fox; John Bastian; Seema Aceves
Journal:  Gastroenterology       Date:  2010-05-07       Impact factor: 22.682

Review 2.  Diagnosis and management of eosinophilic esophagitis.

Authors:  Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2012-06-19       Impact factor: 11.382

3.  Topical viscous budesonide suspension for treatment of eosinophilic esophagitis.

Authors:  Seema S Aceves; Ranjan Dohil; Robert O Newbury; John F Bastian
Journal:  J Allergy Clin Immunol       Date:  2005-09       Impact factor: 10.793

Review 4.  Pediatric and adult eosinophilic esophagitis: similarities and differences.

Authors:  A Straumann; S S Aceves; C Blanchard; M H Collins; G T Furuta; I Hirano; A M Schoepfer; D Simon; H-U Simon
Journal:  Allergy       Date:  2012-02-08       Impact factor: 13.146

Review 5.  Eosinophilic esophagitis--treatment of eosinophilic esophagitis with drugs: corticosteroids.

Authors:  Ulrike von Arnim; Peter Malfertheiner
Journal:  Dig Dis       Date:  2014-02-28       Impact factor: 2.404

6.  Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis.

Authors:  Alex Straumann; Sebastien Conus; Lukas Degen; Stephanie Felder; Mirjam Kummer; Hansjürg Engel; Christian Bussmann; Christoph Beglinger; Alain Schoepfer; Hans-Uwe Simon
Journal:  Gastroenterology       Date:  2010-08-01       Impact factor: 22.682

Review 7.  Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Authors:  Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2011-04-07       Impact factor: 10.793

Review 8.  Non-nutritive sweeteners and their role in the gastrointestinal tract.

Authors:  Rebecca J Brown; Kristina I Rother
Journal:  J Clin Endocrinol Metab       Date:  2012-06-07       Impact factor: 5.958

9.  Comparison of the hedonic general Labeled Magnitude Scale with the hedonic 9-point scale.

Authors:  Jaclyn J Kalva; Charles A Sims; Lorenzo A Puentes; Derek J Snyder; Linda M Bartoshuk
Journal:  J Food Sci       Date:  2014-01-14       Impact factor: 3.167

10.  Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children.

Authors:  Seema S Aceves; John F Bastian; Robert O Newbury; Ranjan Dohil
Journal:  Am J Gastroenterol       Date:  2007-06-20       Impact factor: 10.864

View more
  8 in total

Review 1.  White Paper AGA: Drug Development for Eosinophilic Esophagitis.

Authors:  Ikuo Hirano; Stuart Spechler; Glenn Furuta; Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2017-03-22       Impact factor: 11.382

Review 2.  Management of refractory eosinophilic oesophagitis.

Authors:  Evan S Dellon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-24       Impact factor: 46.802

Review 3.  Red Between the Lines: Evolution of Eosinophilic Esophagitis as a Distinct Clinicopathologic Syndrome.

Authors:  Evan S Dellon
Journal:  Dig Dis Sci       Date:  2020-10-14       Impact factor: 3.199

4.  Variability in Practices of Compounding Budesonide for Eosinophilic Esophagitis.

Authors:  Sagar Joshi; Joel H Rubenstein; Evan S Dellon; Nathan Worthing; Zoe Stefanadis; Joy W Chang
Journal:  Am J Gastroenterol       Date:  2021-06-01       Impact factor: 12.045

Review 5.  Tissue Remodeling in Chronic Eosinophilic Esophageal Inflammation: Parallels in Asthma and Therapeutic Perspectives.

Authors:  Quan M Nhu; Seema S Aceves
Journal:  Front Med (Lausanne)       Date:  2017-08-07

Review 6.  Diagnostic and Therapeutic Long-term Management of Eosinophilic Esophagitis- Current Concepts and Perspectives for Steroid Use.

Authors:  Thomas Greuter; Jeffrey A Alexander; Alex Straumann; David A Katzka
Journal:  Clin Transl Gastroenterol       Date:  2018-12       Impact factor: 4.488

Review 7.  Formulations of Topical Steroids in Eosinophilic Esophagitis-Current Treatment and Emerging Possibilities.

Authors:  Adam Główczewski; Aneta Krogulska
Journal:  J Clin Med       Date:  2022-03-07       Impact factor: 4.241

8.  Transcranial direct current stimulation over the posterior parietal cortex improves visuomotor performance and proprioception in the lower extremities.

Authors:  Yasushi Kamii; Sho Kojima; Hideaki Onishi
Journal:  Front Hum Neurosci       Date:  2022-08-18       Impact factor: 3.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.